217 related articles for article (PubMed ID: 25074566)
1. Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP.
Klehmet J; Goehler J; Ulm L; Kohler S; Meisel C; Meisel A; Harms H
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):686-91. PubMed ID: 25074566
[TBL] [Abstract][Full Text] [Related]
2. Circulating lymphocyte and T memory subsets in glucocorticosteroid versus IVIG treated patients with CIDP.
Klehmet J; Staudt M; Ulm L; Unterwalder N; Meisel A; Meisel C
J Neuroimmunol; 2015 Jun; 283():17-22. PubMed ID: 26004151
[TBL] [Abstract][Full Text] [Related]
3. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
Csurhes PA; Sullivan AA; Green K; Pender MP; McCombe PA
J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1431-9. PubMed ID: 16170091
[TBL] [Abstract][Full Text] [Related]
4. Differences in peripheral myelin antigen-specific T cell responses and T memory subsets in atypical versus typical CIDP.
Staudt M; Diederich JM; Meisel C; Meisel A; Klehmet J
BMC Neurol; 2017 Apr; 17(1):81. PubMed ID: 28446142
[TBL] [Abstract][Full Text] [Related]
5. Efficiency of long-term treatment with intravenous immunoglobulins correlates with reduced autoreactive T cell responses in chronic inflammatory demyelinating polyneuropathy patients.
Klehmet J; Meisel C; Meisel A
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):149-50. PubMed ID: 25546800
[No Abstract] [Full Text] [Related]
6. Recovery of the T-cell repertoire in CIDP by IV immunoglobulins.
Mausberg AK; Dorok M; Stettner M; Müller M; Hartung HP; Dehmel T; Warnke C; Meyer Zu Hörste G; Kieseier BC
Neurology; 2013 Jan; 80(3):296-303. PubMed ID: 23269592
[TBL] [Abstract][Full Text] [Related]
7. Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy.
Sanvito L; Makowska A; Gregson N; Nemni R; Hughes RA
Autoimmunity; 2009; 42(8):667-77. PubMed ID: 19886739
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.
Tackenberg B; Nimmerjahn F; Lünemann JD
J Clin Immunol; 2010 May; 30 Suppl 1():S65-9. PubMed ID: 20424898
[TBL] [Abstract][Full Text] [Related]
9. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
[TBL] [Abstract][Full Text] [Related]
10. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.
Ritter C; Bobylev I; Lehmann HC
J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
[TBL] [Abstract][Full Text] [Related]
12. Influence of impaired T- and B-cell compartments on efficacy of IVIg in dysimmune neuropathies.
Matà S; Corzani S; Biagiotti R; Piacentini S; Siracusa G; Giudizi MG; Mastio MD; Borsini W; Taiuti R; Vultaggio A; Sorbi S; Maggi E
Eur J Neurol; 2007 Oct; 14(10):1147-53. PubMed ID: 17880569
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and availability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy].
Iijima M; Koike H; Sobue G
Nihon Rinsho; 2012 Apr; 70(4):715-21. PubMed ID: 22568158
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; Hahn AF; Vermeulen M; Venance SL; van Doorn PA
J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1331-6. PubMed ID: 25515502
[TBL] [Abstract][Full Text] [Related]
15. IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Ritter C; Förster D; Albrecht P; Hartung HP; Kieseier BC; Lehmann HC
J Neuroimmunol; 2014 Sep; 274(1-2):225-9. PubMed ID: 25002077
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.
Ye Q; Gong FQ; Shang SQ; Hu J
Clin Immunol; 2016 Oct; 171():25-31. PubMed ID: 27519954
[TBL] [Abstract][Full Text] [Related]
18. Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Dyck PJ; Taylor BV; Davies JL; Mauermann ML; Litchy WJ; Klein CJ; Dyck PJ
Muscle Nerve; 2015 Oct; 52(4):488-97. PubMed ID: 25976871
[TBL] [Abstract][Full Text] [Related]
19. Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg.
Korporal-Kuhnke M; Haas J; Schwarz A; Jarius S; Wildemann B
J Neuroimmunol; 2015 Jan; 278():60-8. PubMed ID: 25595253
[TBL] [Abstract][Full Text] [Related]
20. Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulins.
Trebst C; Brunhorn K; Lindner M; Windhagen A; Stangel M
Eur J Neurol; 2006 Dec; 13(12):1359-63. PubMed ID: 17116220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
